NSEGeneral Updates6d ago · 3 Nov 2026, 04:37 pm

General Updates

Patanjali Foods Limited · PATANJALI

✦ AI SummaryRegulatory

Patanjali Foods Limited has informed the Exchange about General Updates regarding action initiated by the Food and Drug Administration (FDA), Maharashtra, concerning certain stock of Patanjali Cow Ghee held by one of its super distributor/Food Business Operators (FBO) in Maharashtra. The Company has been informed of the matter by the concerned FBO and has obtained a copy of the communication for its examination. The Company reiterates its commitment to maintaining the highest standards of product quality, consumer safety and regulatory compliance.

Analysis Scores

Earnings Impact2/10
Growth Catalyst1/10
Governance Concern2/10
Regulatory Risk6/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment4/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Patanjali Foods Limited has informed the Exchange about General Updates

Attachments (1)

📄

RUCHI_03112026163032_Letter.pdf

pdf

Download →
View document text
PFL/2026 November 03, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Tower Exchange Plaza, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 500368 NSE Symbol: PATANJALI Dear Sirs/Madam, Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform you that the Company has come to know about action initiated by the Food and Drug Administration (FDA), Maharashtra, concerning certain stock of Patanjali Cow Ghee held by one of its super distributor/Food Business Operators (FBO) in Maharashtra. In this regard, we wish to place the following facts on record: 1. FDA communication not addressed to the Company The communication/order in relation to the identified stock of Patanjali Cow Ghee was issued to and received by the concerned super distributor/FBO. The said communication has not been addressed or issued directly to the Company. The Company has been informed of the matter by the concerned FBO and has obtained a copy of the communication for its examination. 2. Sampling of Products and Status of Laboratory Reports As per the information and documents made available to the Company, FDA officials collected samples of the concerned batches of Patanjali Cow Ghee for laboratory testing. However, as on the date of this disclosure, neither the Company nor the concerned FBO has received any authenticated laboratory test report establishing that the samples have failed the prescribed quality parameters. It is important to clarify that the collection of samples for testing, by itself, does not establish adulteration, substandard quality or any violation of applicable food safety standards. 3. Direction regarding the Identified Stock As per the communication received by the concerned FBO, directions have been issued regarding the identified stock, including restriction on its sale pending further action. As per the communication available with the Company, the sampling of the product and directions concerning the stock does not, by itself, contain any confirmed laboratory finding establishing adulteration or failure of prescribed quality standards. 4. Company's commitment to quality and regulatory compliance The Company reiterates its commitment to maintaining the highest standards of product quality, consumer safety and regulatory compliance. The Company is taking cognizance of the matter and is seeking relevant details and supporting documents from the concerned FBO and the regulatory authorities. The Company is fully willing to cooperate with the authorities and facilitate independent verification of the concerned batches, as may be required. In the event that any authenticated laboratory report establishes a deviation from the prescribed quality standards, the Company shall examine the findings and take appropriate corrective action in accordance with applicable laws and regulations. 5. Company's position and further developments The Company believes that any conclusion regarding the quality or conformity of the product should be based on authenticated laboratory findings and established regulatory procedures. At present, in the absence of any laboratory report establishing failure of the prescribed quality parameters, it would be premature to conclude that the concerned product is adulterated or substandard. The Company is closely monitoring the matter and shall make further disclosures to the Stock Exchanges, as may be required under applicable SEBI regulations, upon receipt of any material developments or further directions from the concerned regulatory authorities. The Company remains committed to transparency, consumer confidence and compliance with all applicable statutory and regulatory requirements. This is for your information and records please. Thanking you, Yours Faithfully, For Patanjali Foods Limited Ramji Lal Gupta Company Secretary